Provention Bio expects results of inflammatory bowel disease trials in 2H19

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Gilead and partner Galapagos no longer will pursue clinical trials in the United States with filgotinib in rheumatoid arthritis and other conditions, but still could pursue the drug as a treatment for inflammatory bowel disease......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

On-track to report topline data from CLASSICAL-Lung and SIGNAL clinical trials this year Announces expansion of pepinemab development program into Alzheimer's disease Completes private placement of c.....»»

Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière's disease Current capital funds operations into 2021 Conference call and webcast today at 4:.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Acer had below-par results in Asia Pacific in the first ha.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

CE mark received on the initial Immunohematology microarray in April 2019 2018 manufacturing site certification and MosaiQ™ device CE mark combine with the recent approval to permit commercialization Successful European field .....»»

$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1 Start of three Phase II trials for IFX-1 in two serious inflammatory diseases Expansion of our operations along a number of fronts.....»»

The findings could lead to a treatment for inflammatory bowel disease......»»

Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced Phase II U.S. trial f.....»»

Novan Inc (NASDAQ: NOVN) shares were advancing strongly Monday after the announcement of positive results for its pipeline candidate SB414. read more.....»»

UPMC Health Plan announced that the UPMC Center for High-Value Health Care was recently awarded a $6.3 million contract from the Patient-Centered Outcomes Research Institute (PCORI) to improve outcomes for patients with inflammatory bowel disease (.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

A former Amazon employee in Kentucky with the inflammatory bowel condition known as Crohn's disease has sued the company over his dismissal for what he says was a need for more bathroom breaks......»»

SEI Investments (NASDAQ: SEIC) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. read more.....»»

Gary Black expects Tesla's first-quarter results to surpass the consensus adjusted earnings per share estimate of 55 cents per share. read more.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of cosibelimab in metastatic cutaneous squ.....»»